(R)-2-(4-Bromophenyl) Pyrrolidine, sometimes caught in conversation as a brominated pyrrolidine derivative, attracts attention from pharma researchers, specialty chemical suppliers, and anyone paying close attention to raw materials markets. Its chemical structure, C10H12BrN, reflects in a molecular weight around 226.12 g/mol. People who handle R-isomer chiral intermediates will spot its specific density near 1.35 g/cm³, often supplied as solid, white to off-white flakes or powder, melting in the range of 61 – 64°C. CAS number and HS-Code tracking allow for international trade clarity, with demand surging in R&D circles focusing on asymmetric synthesis routes, especially where enantioselective controls count.
Pulling experience from navigating lab procurement, MSDS sheets are not just paperwork—they tell the truth about safe handling and personal protection, whether you’re mixing up a test batch in a GMP-certified clean room or loading raw materials in a bulk processing facility in Jiangsu, China. The document lays out risks: hazardous if swallowed or inhaled, possible irritation to skin and eyes, standard recommendations to suit up with gloves, goggles, N95 masks, and use good ventilation.
Market supply for chiral intermediates like (R)-2-(4-Bromophenyl) Pyrrolidine leans toward efficient production in China, where factories keep costs down without cutting corners on ISO or GMP certifications. Reliable suppliers list product specifications along with REACH, SDS, TDS, or customer-required OEM packaging—crucial for pharma, agrochemical R&D, or diagnostic kits. Purchase options cover sample, MOQ (usually 1–5g for lab testing, kilos for scale-up), CIF or FOB shipping, and plenty of distributors chase bulk orders by offering attractive factory prices, sometimes sweetened by free samples, especially when competing in a robust global market.
Global market reports share some telling numbers. Analysts have tracked multi-digit CAGR for chiral pyrrolidine intermediates in pharma, a sign of growing demand as patents on blockbuster chiral drugs expire and newer candidates enter the clinic. Broad application in CNS-active compounds, synthetic routes for antihypertensives, or emerging APIs (active pharmaceutical ingredients) drives both labs and major factories to keep a tight rein on quality: trace metals below 20ppm, specific optical rotation to confirm R-enantiomer purity, and lot-specific COA from the manufacturer.
Sourcing reliable chemical raw materials calls for more than just a price check. I’ve seen procurement trips cut short by missing ISO or SGS quality certificates, or labs return whole shipments because TDS data indicated hazardous contamination. More distributors now offer full documentation—SGS, Halal, Kosher, even GMP-grade batches. EU supply chains insist on REACH compliance for import clearance; North American buyers won’t touch bulk lots without a complete, up-to-date MSDS. Safety isn’t negotiable: clear labeling, triple-layer packaging, separate storage from oxidizers or strong acids, and on-site eyewash stations make a difference. In the unfortunate event of a spill or exposure, quick action means following the exact steps from the MSDS, not improvising.
Chemical buyers now expect more from manufacturers and suppliers than just low prices. Distillation, crystallization, and optical isomeric purification specifics go under a microscope. Factory audits increasingly verify that production doesn’t just chase output, but limits hazardous emissions and adopts cleanroom discipline in bulk production runs. OEM brands look beyond branding—batch traceability and regular audit trails prove long-term reliability. Certifications matter: ISO 9001, ISO 14001, and specialized pharma GMP standards form the backbone of an audit-ready operation.
Relying on market intelligence helps buyers and distributors pick the right moment for bulk purchases, especially as fluctuations in bromobenzene and pyrrolidine feedstock prices hit ex-factory and FOB pricing. Some buyers watch for regulatory changes—India’s tightening on certain hazardous intermediates or the European Union expanding the list of regulated substances. When market supply gets tight, long-term supplier relationships secure allocation at pre-negotiated rates, and many labs sign MOUs or supply agreements just to lock in stability. Applications continue to spread from pharma intermediates to advanced materials and electronics, pushing both demand and regulatory scrutiny up.
The real conversation comes down to trust: labs and manufacturers working in R&D, scale-up, or downstream formulation know a solid chemical raw material shipment means products that test as pure, shipments that pass customs, and end products that stay on the market without recalls. Factories and distributors taking their job seriously stay nimble: they invest in both tech (quality control, traceable documentation, sealed batch samples) and in people (experienced chemists, hands-on regulatory staff, real 24/7 customer service). By leaning into credible certifications—REACH, ISO, HALAL, KOSHER, SGS—and adapting to the quirks of local and global policy, the industry steps closer to a world where raw materials are safe, available, and able to keep up with the next generation of research and application.
